Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

T-Cell Depleted (TCD) Hematopoietic Stem Cell Transplantation (HCT) For Adult Patients With Acute Myelogenous Leukemia (AML) In First and Second Remission: Long-Term Disease Free Survival(DFS) With a Significantly Reduced Risk Of Graft-Versus-Host Disease(GvHD)

Izaskun Ceberio, MD, Patrick Hilden, MS, Sean M. Devlin, PhD, Molly Maloy, MA, Jenna D Goldberg, MD, Miguel A Perales, MD, Juliet N Barker, MBBS, (Hons), FRACP, Hugo Castro-Malaspina, MD, Guenther Koehne, MD, PhD, Doris M Ponce, MD, Craig S. Sauter, MD, Marcel R.M. van den Brink, MD, PhD, James W. Young, MD, Richard J. O'Reilly, MD, Sergio Giralt, MD, Ann A. Jakubowski, MD, PhD, Esperanza B Papadopoulos, M.D.

Blood (2013) 122 (21): 3387.

https://doi.org/10.1182/blood.V122.21.3387.3387

Published: 2013

Journal Articles

A Phase II Trial of Peri-Transplant Palifermin with Busulfan, Melphalan and Fludarabine Followed by T-Cell Depleted Hematopoietic Stem Cell Transplants in Patients with Advanced Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Evolved From MDS

Roni Tamari, MD, Sheetal Ramnat Sheetal, Deborah Kuk, MS, Esperanza B. Papadopoulos, MD, Ann A. Jakubowski, MD, PhD, Farid Boulad, MD, Trudy N. Small, MD, Nancy A. Kernan, MD, Miguel A Perales, MD, Guenther Koehne, MD, PhD, Doris M Ponce, MD, Sean Devlin, PhD, Jenna D Goldberg, MD, James W. Young, MD, Sergio A Giralt, MD, Richard J. O'Reilly, MD, Hugo R Castro-Malaspina, MD

Blood (2012) 120 (21): 1935.

https://doi.org/10.1182/blood.V120.21.1935.1935

Published: 2012

Journal Articles

Analysis of 121 Allograft Recipients for the Treatment of Lymphoma: Progressive Disease by Functional and/or CT Imaging Is a Critical Determinant of Survival.

Craig S. Sauter, MD, Craig H. Moskowitz, MD, Juliet N. Barker, MBBS, Ann A. Jakubowski, MD, PhD, Esperanza B. Papadopoulos, MD, Miguel A. Perales, MD, James W. Young, MD, Marcel van den Brink, MD, PhD, Andrew D. Zelenetz, MD, PhD, Hugo R. Castro-Malaspina, MD

Blood (2007) 110 (11): 1658.

https://doi.org/10.1182/blood.V110.11.1658.1658

Published: 2007

Journal Articles

Synergistic Tumor Immunity Induced by Chemotherapy and Agonist Anti-GITR Antibody.

Adam D. Cohen, MD, Daniel Hirschhorn-Cymmerman, PhD, Adi Diab, MD, Miguel A. Perales, MD, Taha Merghoub, PhD, Jedd D. Wolchok, MD, PhD, Alan N. Houghton, MD

Blood (2007) 110 (11): 1788.

https://doi.org/10.1182/blood.V110.11.1788.1788

Published: 2007

Journal Articles

Induction of Remission Prior to Transplantation Improves the Disease-Free Survival (DFS) of Patients with Advanced Myelodysplastic Syndromes (MDS) Treated with Myeloablative T-Cell Depleted (TCD) Stem Cell Transplants (SCT) from HLA Identical Siblings.

H.R. Castro-Malaspina, MD, Ann A. Jakubowski, MD, Esperanza B. Papadopoulos, MD, Farid Boulad, MD, James W. Young, MD, Nancy A. Kernan, MD, Miguel A. Perales, MD, Trudy N. Small, MD, Katharina C. Hsu, MD, Michelle Chiu, Glenn Heller, PhD, Marcel van den Brink, MD, Stephen D. Nimer, MD, Richard J. O’Reilly, MD

Blood (2005) 106 (11): 5426.

https://doi.org/10.1182/blood.V106.11.5426.5426

Published: 2005

Journal Articles

A Phase II Trial of Busulfan, Melphalan, and Fludarabine followed by Allogeneic T-Cell Depleted Hematopoietic Stem Cell Transplants from HLA-Identical, or HLA-Non Identical Related or Unrelated Donors for the Treatment of Advanced Hematopoietic Malignancies.

Farid Boulad, MD, Ann Jakubowski, MD, Hugo Castro-Malaspina, MD, Katharine C. Hsu, MD, Nancy A. Kernan, MD, Esperanza B. Papadopoulos, MD, Miguel A. Perales, MD, Susan E. Prockop, MD, Trudy N. Small, MD, Marcel R.M. van den Brink, MD, James W. Young, MD, Michelle Ro, Nancy Collins, PhD, Richard J. O’Reilly, MD

Blood (2004) 104 (11): 1822.

https://doi.org/10.1182/blood.V104.11.1822.1822

Published: 2004

NARROW

T-Cell Depleted (TCD) Hematopoietic Stem Cell Transplantation (HCT) For Adult Patients With Acute Myelogenous Leukemia (AML) In First and Second Remission: Long-Term Disease Free Survival(DFS) With a Significantly Reduced Risk Of Graft-Versus-Host Disease(GvHD)

A Phase II Trial of Peri-Transplant Palifermin with Busulfan, Melphalan and Fludarabine Followed by T-Cell Depleted Hematopoietic Stem Cell Transplants in Patients with Advanced Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Evolved From MDS

Analysis of 121 Allograft Recipients for the Treatment of Lymphoma: Progressive Disease by Functional and/or CT Imaging Is a Critical Determinant of Survival.

Synergistic Tumor Immunity Induced by Chemotherapy and Agonist Anti-GITR Antibody.

Induction of Remission Prior to Transplantation Improves the Disease-Free Survival (DFS) of Patients with Advanced Myelodysplastic Syndromes (MDS) Treated with Myeloablative T-Cell Depleted (TCD) Stem Cell Transplants (SCT) from HLA Identical Siblings.

A Phase II Trial of Busulfan, Melphalan, and Fludarabine followed by Allogeneic T-Cell Depleted Hematopoietic Stem Cell Transplants from HLA-Identical, or HLA-Non Identical Related or Unrelated Donors for the Treatment of Advanced Hematopoietic Malignancies.

Email alerts

ASH Publications

American Society of Hematology

T-Cell Depleted (TCD) Hematopoietic Stem Cell Transplantation (HCT) For Adult Patients With Acute Myelogenous Leukemia (AML) In First and Second Remission: Long-Term Disease Free Survival(DFS) With a Significantly Reduced Risk Of Graft-Versus-Host Disease(GvHD)

A Phase II Trial of Peri-Transplant Palifermin with Busulfan, Melphalan and Fludarabine Followed by T-Cell Depleted Hematopoietic Stem Cell Transplants in Patients with Advanced Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Evolved From MDS

Analysis of 121 Allograft Recipients for the Treatment of Lymphoma: Progressive Disease by Functional and/or CT Imaging Is a Critical Determinant of Survival.

Synergistic Tumor Immunity Induced by Chemotherapy and Agonist Anti-GITR Antibody.

Induction of Remission Prior to Transplantation Improves the Disease-Free Survival (DFS) of Patients with Advanced Myelodysplastic Syndromes (MDS) Treated with Myeloablative T-Cell Depleted (TCD) Stem Cell Transplants (SCT) from HLA Identical Siblings.

A Phase II Trial of Busulfan, Melphalan, and Fludarabine followed by Allogeneic T-Cell Depleted Hematopoietic Stem Cell Transplants from HLA-Identical, or HLA-Non Identical Related or Unrelated Donors for the Treatment of Advanced Hematopoietic Malignancies.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only